Less than 1% of the U.S. population uses cannabis for medical purposes on a regular basis. A key obstacle to mainstream acceptance of cannabis as medical treatment is the lack of clinical trials that demonstrate safety and efficacy of treatment outcomes. The FDA will not allow medical or health claims on cannabis products that have not been proven in clinical trials, which currently cannot be conducted on cannabis as it is considered a dangerous Schedule 1 substance. (The Jerusalem Post)